Helixmith Co

Helixmith Co Assets per Share

The Total Assets per Share of Helixmith Co (084990.KQ) as of Oct 23, 2026 is 3,047.32 KRW. In the previous year, Total Assets per Share was 3,168.46 KRW — a change of -3.82% (lower).

Assets per Share

3,047.32KRW

YoY

-3.82%

Last updated:

Total Assets per Share of Helixmith Co is 2025 3,047.32 KRW. Total Assets per Share of Helixmith Co was 2024 3,168.46 KRW. It decreases by -3.82% lower compared to the previous year.

The Helixmith Co Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2018
6,048.72 KRW
Jan 1, 2019
7,904.44 KRW
Jan 1, 2020
10,175.06 KRW
Jan 1, 2021
6,011.80 KRW
Jan 1, 2022
5,406.59 KRW
Jan 1, 2023
4,836.65 KRW
Jan 1, 2024
3,168.46 KRW
Jan 1, 2025
3,047.32 KRW
The Helixmith Co Assets per Share history
YEARAssets per ShareYoY
3,047.32KRW-3.82%
3,168.46KRW-34.49%
4,836.65KRW-10.54%
5,406.59KRW-10.07%
6,011.80KRW-40.92%
10,175.06KRW+28.73%
7,904.44KRW+30.68%
6,048.72KRW+58.45%
3,817.38KRW+0.76%
3,788.71KRW+152.14%
1,502.62KRW+0.34%
1,497.50KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Helixmith Co Stock analysis

What does Helixmith Co do? Helixmith Co., Ltd. generates revenue through its Natural Products Business segment, which develops and sells raw materials for functional materials and health functional foods under brands like Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment focuses on developing treatments for diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer therapies. Customers include companies in the health and pharmaceutical sectors seeking natural ingredients and specialized medical treatments. The company serves two distinct market segments: one for natural product raw materials and another for advanced biopharmaceutical solutions. The Natural Products Business segment targets clients requiring raw materials for functional materials and health functional foods, leveraging branded products Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment caters to healthcare providers and pharmaceutical firms developing treatments for specific medical conditions, including diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer applications. Both segments operate within the broader health and biotechnology industries, with the company's revenue streams derived from product sales across these specialized markets. Helixmith Co., Ltd. monetizes its research and development efforts through the commercialization of natural substance-based raw materials and biopharmaceutical treatments. The company's product portfolio includes Alex, Murphine, and Nimosin for the natural products market, while its biopharmaceutical segment offers treatments for diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer conditions. Revenue is generated from direct sales to businesses in the health, functional food, and pharmaceutical sectors, with no mention of additional revenue streams such as licensing or partnerships. Helixmith Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Helixmith Co stock

Total Assets per Share of Helixmith Co is 3,047.32 KRW in 2025.

Total Assets per Share of Helixmith Co changed from 3,168.46 KRW to 3,047.32 KRW, representing a -3.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Helixmith Co since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Helixmith Co

All Key Metrics — Helixmith Co